The kit, for which Sherlock Biosciences recently received Emergency Use Authorization by the US Food and Drug Administration, will be used to test clinical samples from patients from D-HH member hospitals.
The Sherlock CRISPR SARS-CoV-2 test kit is designed for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, 42 USC. §263a, to perform high complexity tests.
Based on the SHERLOCK method, which stands for Specific High-sensitivity Enzymatic Reporter unLOCKing, the kit works by programming a CRISPR nuclease to detect the presence of a specific genetic signature in this case, the genetic signature for SARS-CoV-2 in a nasal swab, nasopharyngeal swab, oropharyngeal swab or bronchoalveolar lavage specimen.
When the signature is found, the CRISPR enzyme is activated and cuts reporter RNAs provided as part of the kit to release a detectable signal, yielding results in about an hour.
It is the first and only CRISPR-based diagnostic test to receive EUA from the FDA for qualitative detection of nucleic acid from SARS-CoV-2.
Dartmouth-Hitchcock Health is New Hampshire's only academic health system and the state's largest private employer. It serves a population of 1.9m across Northern New England.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients